Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasone-mediated glucocorticoid receptor signals

Molecular Cancer Therapeutics

Volumn 11, Issue 12, 2012, Pages 2621-2632

  Zheng, Yichun ^a,b   Izumi, Koji ^a   Li, Yi ^a,b   Ishiguro, Hitoshi ^a   Miyamoto, Hiroshi ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DEXAMETHASONE; GELATINASE A; GELATINASE B; GLUCOCORTICOID RECEPTOR; GLUCOCORTICOID RECEPTOR ANTAGONIST; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES; BLADDER CANCER; CANCER GROWTH; CANCER INVASION; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSOL; DRUG EFFICACY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DEXAMETHASONE; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MALE; MICE; MICE, SCID; NEOPLASM INVASIVENESS; NF-KAPPA B; RECEPTORS, GLUCOCORTICOID; TRANSCRIPTIONAL ACTIVATION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871367918     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0621     Document Type: Article

References (20)

1. Goebell PJ, Knowles MA. Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium. Urol Oncol 2010;28:409-28.
2. Miyamoto H, Miller JS, Fajardo DA, Lee TK, Netto GJ, Epstein JI. Noninvasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system. Pathol Int 2010;60:1-8.
3. Schlossmacher G, Stevens A, White A. Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 2011;211:17-25.
4. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-46. (Pubitemid 33130263)
5. Zhang C, Mattern J, Haferkamp A, Pfitzenmaier J, Hohenfellner M, Rittgen W, et al. Corticosteroid-induced chemotherapy resistance in urological cancers. Cancer Biol Ther 2006;5:59-64. (Pubitemid 43234979)
6. Zhang C, Wenger T, Mattern J, Ilea S, Frey C, Gutwein P, et al. Clinical and mechanistic aspects of glucocorticoid-induced chemotherapy resistance in the majority of solid tumors. Cancer Biol Ther 2007;6:e1-9.
7. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011;29:4189-98.
8. Dietrich K, Schned A, Fortuny J, Heaney J, Marsit C, Kelsey KT, et al. Glucocorticoid therapy and risk of bladder cancer. Br J Cancer 2009;101:1316-20.
9. Miyamoto H, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, et al. Promotion of bladder cancer development and progression by androgen receptor signals. J Natl Cancer Inst 2007;99:558-68. (Pubitemid 47078733)
10. Sonpavde G, Okuno N, Weiss H, Yu J, Shen SS, Younes M, et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 2007;69:1221-6. (Pubitemid 46891583)
11. Miyamoto H, Zheng Y, Izumi K. Nuclear hormone receptor signals as new therapeutic targets for urothelial carcinoma. Curr Cancer Drug Tar 2012;12:14-22.
12. Zheng Y, Izumi K, Yao JL, Miyamoto H. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocr Relat Cancer 2011;18:451-64.
13. Izumi K, Zheng Y, Hsu J-W, Chang C, Miyamoto H. Androgen receptor signals regulate UDP-glucuronosyltransferases in the urinary bladder: a potential mechanism of androgen-induced bladder carcinogenesis. Mol Carcinog 2011 Nov 15. [Epub ahead of print].
14. Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001;20:4188-97. (Pubitemid 32762193)
15. Rogatsky I, Trowbridge JM, Garabedian MJ. Glucocorticoid receptor-mediated cell cycle arrest is achieved through distinct cell-specific regulatory mechanisms. Mol Cell Biol 1997;17:3191-3.
16. Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol 1999;13:1811-22.
17. Chung YJ, Lee JI, Chong S, Seok JW, Park SJ, Jang HW, et al. Anti-proliferative effect and action mechanism of dexamethasone in human medullary thyroid cancer cell line. Endocr Res 2011;36:149- 57.
18. Mian BM, Dinney CPN, Bermejo CE, Sweeney P, Tellez C, Yang XD, et al. Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-κB. Clin Cancer Res 2003;9:3167-75. (Pubitemid 36993279)
19. Zhang L, Lei W, Wang X, Tang Y, Song J. Glucocorticoid induces mesenchymal-to-epithelial transition and inhibits TGF-β1-induced epithelial-to-mesenchymal transition and cell migration. FEBS Lett 2010;584:4646-54.
20. McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, et al. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 2009;28:335-44.